Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc ACHFF


Primary Symbol: V.ARCH

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.


TSXV:ARCH - Post by User

Arch Biopartners Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(302)
•••
Post by Viking2233on Jun 28, 2023 8:31pm
123 Views
Post# 35519618

Somethings smells here

Somethings smells hereYesterday's new release of FDA approval for AKI phase 2 trial should have caught the attention of any interested investors. IMO yesterdays news should have got us back up to $5 with high volume. We had a mild bump up Monday and Tuesday (news release) to the tune of 15%. Today CIBC and Scotiabank knocked us on our a.. today closing down 5.25%. Something fishy here.

Just the mention of FDA would spark buying interest.

The other intresting point is there are multiple similar staged companies who have market caps of $1B to $2B and we are stuck at $125M. We know we have the science but why the major difference?? Something is not adding up here? Where are the buyers? 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities